Reigniting p53

Our peptide-based cancer therapeutic approach is based on reeducating mutant p53 protein to regain wild type functionality, resuming its role as the guardian of our genome.

01

We are Quintrigen

We are on the road to correct mutated p53, whose dysfunction is responsible for 50% of all cancers. Our team of world-renowned scientists has been at the forefront of p53 research for more than four decades and we are backed by top international strategic partners.

Read more about Quintrigen
02

Targeting p53: A guardian gone rogue

The normal wild type p53 is the most powerful tumor suppressor. It can prevent cancer by instructing the repair of damaged DNA, or alternatively triggering cell destruction when the DNA is irreparable. But p53 may stray from the path nature assigned it. The p53 gene itself can be damaged and become mutant, not only losing its tumor suppressor abilities but sometimes gaining oncogenic activities, opening the gate to cancer.

Learn more about p53
03

Our unique peptide-based approach

Quintrigen has identified a family of small peptides that can reeducate mutant p53 to resume its guardian job. With a touch of these peptides, we can refold mutant p53 into its natural conformation, stabilizing its structure and restoring its potent guardian activity.

Read more about our approach
01

We are Quintrigen

We are on the road to correct mutated p53, whose dysfunction is responsible for 50% of all cancers. Our team of world-renowned scientists has been at the forefront of p53 research for more than four decades and we are backed by top international strategic partners.

Read more about Quintrigen
02

Targeting p53: A guardian gone rogue

The normal wild type p53 is the most powerful tumor suppressor. It can prevent cancer by instructing the repair of damaged DNA, or alternatively triggering cell destruction when the DNA is irreparable. But p53 may stray from the path nature assigned it. The p53 gene itself can be damaged and become mutant, not only losing its tumor suppressor abilities but sometimes gaining oncogenic activities, opening the gate to cancer.

Learn more about p53
03

Our unique peptide-based approach

Quintrigen has identified a family of small peptides that can reeducate mutant p53 to resume its guardian job. With a touch of these peptides, we can refold mutant p53 into its natural conformation, stabilizing its structure and restoring its potent guardian activity.

Read more about our approach
quote

It is as though we can turn the mutant p53 protein from foe to friend all at once.

Prof. Varda Rotter

Meet our founders